Forte Biosciences, Inc. — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
argenx BV agreed to acquire all outstanding shares of Forte Biosciences, Inc. for $77.00 per share in an all-cash tender offer, valuing the company at approximately $1.58 billion (20.49 million shares × $77). The merger agreement was executed July 26, 2026, with the Offer to commence within 10 business days. The transaction is structured as a two-step: tender offer followed by merger under DGCL Section 251(h), requiring no stockholder vote post-acceptance. Board unanimously approved; Supporting Stockholders committed to tender.
Why this rating
At $1.58B purchase price versus $157M market cap (~10x), this is transformational—entire company being acquired at significant premium. Deal changes business trajectory completely.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.